References
- World Federation of Haemophilia (2019) Report on the Annual Global
Survey 2018. WFH, Montreal, Canada.http://www1.wfh.org/publications/files/pdf-1731.pdf.
Accessed May 20, 2020
- Regulation (EC) No. 141/2000 of the European Parliament and of the
Council.https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32000R0141&from=EN.
Accessed May 20, 2020.
- Giannelli F, Green PM. The molecular basis of haemophilia A and
B. Baillieres Clin Haematol . 1996;9(2):211-228.
doi:10.1016/s0950-3536(96)80059-x.
- Weyand AC, Pipe SW. New therapies for hemophilia. Blood .
2019;133(5):389-398. doi:10.1182/blood-2018-08-872291.
- Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for
hemophilia. Blood . 2019;133(5):407-414.
doi:10.1182/blood-2018-07-820720.
- Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of
AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med .
2020;382(1):29-40. doi:10.1056/NEJMoa1908490.
- Iorio A, Stonebraker JS, Chambost H, et al. Establishing the
Prevalence and Prevalence at Birth of Hemophilia in Males: A
Meta-analytic Approach Using National Registries. Ann Intern
Med . 2019;171(8):540-546. doi:10.7326/M19-1208.
- Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for
the management of hemophilia. Haemophilia . 2013;19(1):e1-e47.
doi:10.1111/j.1365-2516.2012.02909.x.
- White GC 2nd, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular
immune responses in hemophilia: why do inhibitors develop in some, but
not all hemophiliacs?. J Thromb Haemost . 2005;3(8):1676-1681.
doi:10.1111/j.1538-7836.2005.01375.x,
- Oldenburg J. Optimal treatment strategies for hemophilia: achievements
and limitations of current prophylactic regimens. Blood .
2015;125(13):2038-2044. doi:10.1182/blood-2015-01-528414.
- Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM; US Hemophilia
Treatment Center Network. Men with severe hemophilia in the United
States: birth cohort analysis of a large national
database. Blood . 2016;127(24):3073-3081.
doi:10.1182/blood-2015-10-675140.
- Di Minno MND, Pasta G, Airaldi S, et al. Ultrasound for Early
Detection of Joint Disease in Patients with Hemophilic
Arthropathy. J Clin Med . 2017;6(8):77. doi:10.3390/jcm6080077.
- Shima M, Hanabusa H, Taki M, et al. Factor VIII-Mimetic Function of
Humanized Bispecific Antibody in Hemophilia A. N Engl J Med .
2016;374(21):2044-2053. doi:10.1056/NEJMoa1511769.
- Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no
prophylaxis in phase III HAVEN 3 study in haemophilia A without factor
VIII inhibitors.https://www.roche.com/media/releases/med-cor-2018-05-21.htm.
Accessed on May 20, 2020.
- Miyazaki, K. (2013) Coagulation of Blood. In: Gellman M.D., Turner
J.R. (eds) Encyclopedia of Behavioral Medicine. Springer, New York,
NY.
- Shetty S, Vora S, Kulkarni B, et al. Contribution of natural
anticoagulant and fibrinolytic factors in modulating the clinical
severity of haemophilia patients. Br J Haematol .
2007;138(4):541-544. doi:10.1111/j.1365-2141.2007.06693.x.
- Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of Antithrombin in
Hemophilia A or B with RNAi Therapy. N Engl J Med .
2017;377(9):819-828. doi:10.1056/NEJMoa1616569.
- Machin N, Ragni MV. An investigational RNAi therapeutic targeting
antithrombin for the treatment of hemophilia A and B. J Blood
Med . 2018;9:135-140. doi:10.2147/JBM.S159297.
- Farkas AM, Mariz S, Stoyanova-Beninska V, et al. Advanced Therapy
Medicinal Products for Rare Diseases: State of Play of Incentives
Supporting Development in Europe. Front Med (Lausanne) .
2017;4:53. Published 2017 May 16. doi:10.3389/fmed.2017.00053.
- Chuah MK, Evens H, VandenDriessche T. Gene therapy for
hemophilia. J Thromb Haemost . 2013;11 Suppl 1:99-110.
doi:10.1111/jth.12215.
- Swystun LL, Lillicrap D. Gene Therapy for Coagulation
Disorders. Circ Res . 2016;118(9):1443-1452.
doi:10.1161/CIRCRESAHA.115.307015.
- Chapin JC, Monahan PE. Gene Therapy for Hemophilia: Progress to
Date. BioDrugs . 2018;32(1):9-25. doi:10.1007/s40259-017-0255-0.
- Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective
virus particles. Science . 1965;149(3685):754-756.
doi:10.1126/science.149.3685.754.
- ClinicalTrials.gov.https://clinicaltrials.gov/ct2/home.
Accessed on May 20, 2020.
- EU Clinical Trials Register.https://www.clinicaltrialsregister.eu/.
Accessed on May20, 2020.
- Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and
efficacy of factor IX gene therapy in hemophilia B. N Engl J
Med . 2014;371(21):1994-2004. doi:10.1056/NEJMoa1407309.
- Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future
hold?. Ther Adv Hematol . 2018;9(9):273-293. Published 2018 Aug
27. doi:10.1177/2040620718791933.
- Ide LM, Gangadharan B, Chiang KY, Doering CB, Spencer HT.
Hematopoietic stem-cell gene therapy of hemophilia A incorporating a
porcine factor VIII transgene and nonmyeloablative conditioning
regimens. Blood . 2007;110(8):2855-2863.
doi:10.1182/blood-2007-04-082602.
- Sangamo Therapeutics (2018). Sangamo announces treatment of first
patient in phase 1/2 clinical trial of in vivo genome editing therapy
for hemophilia B.https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-treatment-first-patient-phase-12-clinical-0.
Accessed on May 20, 2020.
- Herzog RW. Hemophilia Gene Therapy: Caught Between a Cure and an
Immune Response. Mol Ther . 2015;23(9):1411-1412.
doi:10.1038/mt.2015.135.
- Mingozzi F, High KA. Immune responses to AAV vectors: overcoming
barriers to successful gene therapy. Blood . 2013;122(1):23-36.
doi:10.1182/blood-2013-01-306647.